STOCKHOLDERS' EQUITY

3 Months Ended

May 31, 2022

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 11 – STOCKHOLDERS’ EQUITY

Stock-based compensation expense is included in the following captions of the condensed consolidated statements of comprehensive loss (in thousands):

	Three Months Ended
	May 31,
	2022		2021
Cost of revenues	$	55	$	(6	)
Research and development		764		710
Selling and marketing		560		644
General and administrative		1,581		1,060
Other non-operating expense		—		64
	$	2,960	$	2,472

Changes in our outstanding stock options during the three months ended May 31, 2022 were as follows (options in thousands):

	Number of Options		Weighted Average Exercise Price		Weighted average remaining contractual life (years)		Aggregate intrinsic value
Outstanding at February 28, 2022		664	$	16.38		5.4
Granted		—		—
Exercised		—		—
Forfeited or expired		—		—
Outstanding at May 31, 2022		664	$	16.38		5.1	$	—
Exercisable at May 31, 2022		556	$	15.98		4.9	$	—

Changes in our outstanding restricted stock shares, performance stock units (“PSUs”) and restricted stock units (“RSUs”) during the three months ended May 31, 2022 were as follows (restricted shares, PSUs and RSUs in thousands):

	Number of Restricted Shares, PSUs and RSUs			Weighted Average Grant Date Fair Value		Shares Retained to Cover Statutory Minimum Withholding Taxes
Outstanding at February 28, 2022		2,940		$	10.39
Granted		97			6.72
Vested		(187	)		9.92		82
Forfeited		(109	)		10.68
Outstanding at May 31, 2022		2,741		$	10.28

As of May 31, 2022, there was $17.9 million of total unrecognized stock-based compensation cost related to outstanding nonvested equity awards that is expected to be recognized as an expense over a weighted-average remaining vesting period of 2.0 years.